SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-059556
Filing Date
2024-05-14
Accepted
2024-05-14 16:12:31
Documents
59
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q antx-20240331.htm   iXBRL 10-Q 1820257
2 EX-10.1 antx-ex10_1.htm EX-10.1 18504
3 EX-31.1 antx-ex31_1.htm EX-31.1 16512
4 EX-31.2 antx-ex31_2.htm EX-31.2 16807
5 EX-32.1 antx-ex32_1.htm EX-32.1 8530
6 EX-32.2 antx-ex32_2.htm EX-32.2 8345
  Complete submission text file 0000950170-24-059556.txt   6751349

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT antx-20240331.xsd EX-101.SCH 968422
63 EXTRACTED XBRL INSTANCE DOCUMENT antx-20240331_htm.xml XML 973389
Mailing Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027
Business Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027 (650) 331-9090
AN2 Therapeutics, Inc. (Filer) CIK: 0001880438 (see all company filings)

IRS No.: 820606654 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41331 | Film No.: 24944475
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)